| ［1］ |
Torrelo A, Zambrano A, Happle R. Cutis marmorata telangiectatica congenita and extensive mongolian spots: type 5 phacomatosis pigmentovascularis［J］. Br J Dermatol, 2003,148（2）:342⁃345. doi: 10.1046/j.1365⁃2133.2003.05118.x.
|
| ［2］ |
Thomas AC, Zeng Z, Rivière JB, et al. Mosaic activating mutations in GNA11 and GNAQ are associated with phakomatosis pigmentovascularis and extensive dermal melanocytosis［J］. J Invest Dermatol, 2016,136（4）:770⁃778. doi: 10.1016/j.jid.2015.11.027.
|
| ［3］ |
Groesser L, Herschberger E, Sagrera A, et al. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell［J］. J Invest Dermatol, 2013,133（8）:1998⁃2003. doi: 10.1038/jid.2013.24.
|
| ［4］ |
Dutta A, Ghosh SK, Bandyopadhyay D, et al. Phakomatosis pigmentovascularis: a clinical profile of 11 Indian patients［J］. Indian J Dermatol, 2019,64（3）:217⁃223. doi: 10.4103/ijd.IJD_385_18.
|
| ［5］ |
Patil B, Sinha G, Nayak B, et al. Bilateral Sturge⁃Weber and phakomatosis pigmentovascularis with glaucoma, an overlap syndrome［J］. Case Rep Ophthalmol Med, 2015,2015:106932. doi: 10.1155/2015/106932.
|
| ［6］ |
Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma［J］. Br J Cancer, 2011,104（3）:392⁃398. doi: 10.1038/sj.bjc.6606030.
|
| ［7］ |
何瑞, 张斌, 李丽, 等. 外用西罗莫司治疗儿童浅表脉管畸形19例的临床疗效及安全性分析［J］. 中华皮肤科杂志, 2022,55（2）:129⁃134. doi: 10.35541/cjd.20210629.
|
| ［8］ |
张斌, 李丽, 尉莉, 等. 口服西罗莫司治疗儿童复杂性静脉畸形的效果和安全性: 一项单中心前瞻性研究. 中华整形外科杂志, 2020,36（5）:483⁃493. doi: 10.3760/cma.j.cn114453⁃2020 0315⁃00152.
|
